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Abstract
Protein kinase CK2 is frequently up-regulated in human cancers, although the mechanism of CK2 activation in cancer
remains unknown. In this study, we investigated the role of the CK2a intronless gene (CSNK2A1P, a presumed CK2a
pseudogene) in the pathogenesis of human cancers. We found evidence of amplification and over-expression of the
CSNK2A1P gene in non- small cell lung cancer and leukemia cell lines and 25% of the lung cancer tissues studied. The
mRNA expression levels correlated with the copy numbers of the CSNK2A1P gene. We also identified a novel polymorphic
variant (398T/C, I133T) of the CSNK2A1P gene and showed that the 398T allele is selectively amplified over the 398C allele
in 101 non-small cell lung cancer tissue samples compared to those in 48 normal controls (p=0.013,0.05). We show for
the first time CSNK2A1P protein expression in transfected human embryonic kidney 293T and mouse embryonic fibroblast
NIH-3T3 cell lines. Both alleles are transforming in these cell lines, and the 398T allele appears to be more transforming
than the 398C allele. Moreover, the 398T allele degrades PML tumor suppressor protein more efficiently than the 398C
allele and shows a relatively stronger binding to PML. Knockdown of the CSNK2A1P gene expression with specific siRNA
increased the PML protein level in lung cancer cells. We report, for the first time, that the CSNK2A1P gene is a functional
proto-oncogene in human cancers and its functional polymorphism appears to degrade PML differentially in cancer cells.
These results are consistent with an important role for the 398T allele of the CSNK2A1P in human lung cancer
susceptibility.
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Introduction
Lung cancer is the leading cause of death from cancer in the
United States [1]. Some of the somatic events involved in lung
cancer have been well characterized, but some of them remain
unknown [2,3]. Protein kinase CK2 (formerly known as casein
kinase II) is a serine/threonine protein kinase that phosphorylates
more than 300 proteins [4]. It degrades tumor suppressor proteins
such as PML [5] and promotes the activity and stability of
oncogenic proteins such as AKT [6]. For instance, CK2 promotes
PML degradation and CK2 kinase activity is inversely correlated
with PML protein levels in human lung cancer [5]. Recently,
multiple myeloma cell survival was shown to rely on the high
activity of protein kinase CK2 [7]. CK2 also affects several
cell signaling pathways, including PI3K, NFkB, and Wnt
pathways [8].
The level of CK2a expression is tightly regulated in normal cells
[9], and increased CK2a level and activity has consistently been
observed in a variety of human cancers [10]. For instance, the
high-level and/or nuclear localization of CK2a is a marker of poor
prognosis for patients with acute myeloid leukemia, prostate
cancer, and squamous cell lung cancer [10]. CK2a is the catalytic
subunit of protein kinase CK2 and CK2a has been reported to be
coded by the CSNK2A1 gene on chromosome 20p13 [11]. The
CSNK2A1 gene can serve as an oncogene and its dysregulated
expression can induce mammary tumors and lymphomas in
transgenic mice [12,13]. Although the activity of the CSNK2A1
gene has been shown to be elevated in human cancers, no solid
genetic or epigenetic evidence is available regarding the cause of
the high-activity of CK2a in cancer cells [10]. The CK2a
intronless gene (also known as CK2a ‘‘pseudogene’’), CSNK2A1P,
is located on chromosome 11p15.3 and its sequence is highly
homologous (99% identity) to the CSNK2A1 cDNA sequence [14].
Although the CSNK2A1P gene is reportedly expressed in a
megakaryocytic cell line [15], its role in cancer cell development
remains unknown. We therefore investigated the amplification and
expression of the CSNK2A1P gene in lung cancer and leukemia cell
lines and lung cancer tissues.
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Over-expression and amplification of the CSNK2A1P gene
in cancer cells and lung cancer tissues
We focused on the CSNK2A1P gene because we initially found it
was minimally expressed in normal cells, but was predominantly
expressed in several types of human cancer cell lines and tumor
tissues, including the human T cell leukemia cell line Jurkat, which
is known for its high CK2 activity. By semi-quantitative RT-PCR,
we showed that the CSNK2A1P gene is also over-expressed in three
NSCLC lines: H1299, H322, and A549, but minimally expressed
in normal cells and two lung cancer cell lines H1650 and H460
(Fig. 1A). Furthermore, CSNK2A1P mRNA was overexpressed in
lung tumor tissue from seven out of 29 (,25%) tumor samples as
compared to matched control tissues (Fig. 1B). Moreover, FISH
analysis on the same human cancer cell lines provided solid
evidence of the amplification of the CSNK2A1P gene located on
chromosome 11p15.3 (Fig. 1D). For example, four copies of the
CSNK2A1P gene were found in the human T cell leukemia cell line
Jurkat, and three copies in the lung cancer cell lines H1299, A549,
and H322. In contrast, normal lymphocytes and H460 cell line
had diploid copies of the CSNK2A1P gene (Fig. 1C and D).
Importantly, mRNA expression levels correlated with copy
numbers of the CSNK2A1P gene in these human cancer cell lines
(n=8; pearson’s c=0.9346; p=0.0007) (Fig. 1 E). We further
performed semi-quantitative RT-PCR to evaluate the mRNA
expression of the CSNK2A1 gene with specific primers. Overex-
pression of the CSNK2A1 gene was also noted in above cancer cell
lines (Fig. 1F), suggesting that in addition to the CSNK2A1 gene,
the CSNK2A1P gene also plays important roles in the pathogenesis
of lung cancer. Alignment of the primers used for semi-
quantitative RT-PCR of the CSNK2A1 and CSNK2A1P genes were
shown in supplementary data (Fig. S1).
Allele-specific amplification of the CSNK2A1P gene in
lung cancer
To determine whether there are any mutations of CSNK2A1P in
human lung cancers, we sequenced the open reading frame of the
CSNK2A1P gene. Although we did not find any mutations, we
discovered a novel polymorphism within the kinase domain
(398T/C, which leads to amino acid change I133T, Fig. 2A) in 18
cancer cell lines (Table 1) and 101 primary lung cancer tissue
samples (Table 2). The specific amino acid change is predicted to
affect the protein function when the sorting intolerant from
tolerant (SIFT) method is used [16]. Interestingly, this polymor-
phism appeared to be evenly distributed in normal tissue, but in
tumors, was significantly more frequent at the 398T allele (Fig. 2C)
(Chi-Square test, p,0.05). Furthermore, of the 56 heterozygous
lung cancer tissues examined with respect to this polymorphism
(Fig. 2D), 20 (35.7%) samples showed amplification in this region,
and in 18 (90%) of those 20 samples, the 398T allele was
selectively amplified (Fig. 2E). This selective amplification suggests
that the 398T allele might provide a growth advantage over the
398C allele. To further validate the results from DNA sequencing,
we investigated the allele-specific amplification of the 398T allele
of CSNK2A1P (encoding the Ile133 variant) in human tumors using
a quantitative single nucleotide polymorphism (SNP) analysis, i.e.,
TaqMan-based allelic discrimination assay. The allelic discrimi-
nation data is consistent with the sequencing data (Fig. 2B). Of the
101 lung tumor samples typed, 56 were heterozygous with respect
to the 398CRT polymorphism, and we analyzed these 56 samples
for allele-specific amplification of the 398CRT polymorphism of
CSNK2A1P by TaqMan analysis (Fig. 2B). Twenty samples showed
allelic imbalance between the two alleles, 2 samples showed gain of
the 398C allele (encoding Thr133) and 18 samples showed gain of
the 398T allele (encoding Ile133). These results show statistically
significant allele-specific amplification of the 398T allele (P,0.05,
Chi-Square test), providing additional evidence for the role of this
allele in human lung cancer. These results prompted us to probe
more deeply into the role of the variant CSNK2A1P forms in tumor
development.
Differential transforming activity of the two CSNK2A1P
alleles
To test the functional significance of the 398TRC polymor-
phism in the CSNK2A1P gene, we cloned the CSNK2A1 and
CSNK2A1P genes into pcDNA 3.1/myc-His vector and carried out
a series of cell growth assays using NIH3T3 cells. In this study,
these vectors were transiently transfected into 293T and NIH3T3
cells and western analysis was used to confirm the protein
expression of both alleles of the CSNK2A1P gene (Fig. 3A). The
results show, for the first time, that the expression of CSNK2A1P
can produce its proteins.
In the colony formation assay, transfection of CSNK2A1P
genes in NIH3T3 (NIH3T3-CSNK2A1P) cells results in
enhanced anchorage-dependent growth, compared to the empty
vector control (NIH3T3-EV). In addition, we generated
NIH3T3 cells with CSNK2A1 (NIH3T3-CSNK2A1) as a
positive control. The colony numbers of NIH3T3-CSNK2A1
and NIH3T3-CSNK2A1P cells were dramatically higher than
t h o s eo ft h eN I H 3 T 3 - E Vc e l l s( F i g .3 B ) .T r a n s f e c t i o no ft h e
CSNK2A1P gene in NIH3T3 cells also resulted in enhanced
anchorage-independent growth. When soft agar colony forma-
tion assay results were compared, we found that stable
transfection of CSNK2A1P genes in NIH3T3 cells resulted in
enhanced anchorage-independent growth (Figure 3C). Both the
NIH3T3-CSNK2A1 and NIH3T3-CSNK2A1P cells produced
more colonies than the NIH3T3-EV cells did. Compared to the
NIH3T3-EV cells, NIH3T3-CSNK2A1 and NIH3T3-
CSNK2A1P cells produced colonies that were mostly bigger
and had spread-out shapes. When the two alleles of the
CSNK2A1P genes were compared, we found that the 398T allele
formed more colonies than the 398C allele did. A kinase assay of
the expressed proteins was also performed (Figure 3D). The
398T gene product has a higher kinase activity than the 398C
gene product does. The results from the kinase assay are
consistent with the colony formation and soft agar data.
Functional polymorphism of the CSNK2A1P genes on the
degradation of PML tumor suppressor protein
To determine the potential mechanism by which the 398T allele
is preferentially amplified in lung cancer samples, we studied the
effects of the two alleles of the CSNK2A1P gene on tumor
suppressor PML protein. The CSNK2A1P genes were stably
transfected into NIH3T3 and NSCLC H1650 cell lines. Western
blot analysis showed a reduced PML protein level in the cells
transfected with the CSNK2A1P genes. The CSNK2A1P 398T
allele, similar to wild-type CSNK2A1, decreased PML protein
levels more than the 398C allele did (Fig. 4A). Second, we
determined whether the half-life of PML is differentially regulated
by the two alleles. These two cell lines transfected with the
CSNK2A1P gene were treated with cycloheximide for 0, 2, and
6 hours, and the endogenous PML protein levels were examined.
The 398T allele decreased the half-life of PML more effectively
than the 398C allele did (Fig. 4B). Third, we used co-
immunoprecipitation to show the direct and preferential binding
between the 398T protein and PML protein (Fig. 4C).
CK2 Pseudogene in Lung Cancer
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mRNA is fully translated and degrades PML in cancer cells, we
knocked down the CSNK2A1P gene in H1299 lung cancer cell lines
with siRNA specific to the CSNK2A1P gene. We chose the H1299
lung cancer cell line because our study (Figure 1A and C) showed
that the CSNK2A1P gene is amplified and overexpressed in this cell
line. The CSNK2A1P gene specific siRNA caused a greater than
70% decrease in the expression of the CSNK2A1P gene and no
decrease in the expression of the CSNK2A1 and CSNK2B genes
(Fig. 4D). In accordance with decreased expression of the
Figure 1. CSNK2A1P gene overexpression amplification in human cancer cell lines and primary tumors. (A) Semi-quantitative RT-PCR
using CSNK2A1P-specific primers shows the CSNK2A1P mRNA expression level is consistent with the copy numbers detected by FISH (3 for H1299, 4
for Jurkat, 3 for H322 and A549, 2 for WI-38 and CCL-211). (B) Semi-quantitative RT-PCR using CSNK2A1P-specific primers shows the CSNK2A1P mRNA
is overexpressed in seven (patient 1 to 7) out of 29 (,25%) lung tumors as compared to matched normal adjacent tissue. Patient 8 to 14 represents
samples without overexpressed CSNK2A1P mRNA. Other 14 samples with similar results are not shown. (C) The CSNK2A1P gene is amplified in the
human T cell leukemia cell line Jurkat, and in lung cancer cell lines H1299, A549, and H322. (D) Representative pictures of FISH study results in
metaphases of normal lymphocyte, Jurkat, H322 and A549 cell lines. The CSNK2A1P gene was labeled with Cy3 (in red). Chromosome 11 centimeter
probe was labeled with FITC (in green). (E) Correlation of the copy number and mRNA expression the CSNK2A1P gene was calculated using pearson
correlation. (F) Semi-quantitative RT-PCR using CSNK2A1-specific primers shows the CSNK2A1 mRNA expression level in normal and cancer cell lines
mentioned above. All semi-quantitative RT-PCR experiments were repeated three times with similar results.
doi:10.1371/journal.pone.0011418.g001
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protein increased in the cells treated with CSNK2A1P siRNAs
compared to negative siRNA transfected controls (Fig. 4E).
Discussion
In this study, we have provided, to our knowledge, the first
evidence to show that the CSNK2A1P gene is a functional proto-
oncogene in human cancers. To support our hypothesis that
CSNK2A1P gene is a functional proto-oncogene, rather than a
‘‘pseudogene’’, we have done extensive DNA, mRNA, protein and
siRNA analysis. The results of this analysis provide the first
evidence that the mRNA expression level correlates with the copy
number of the CSNK2A1P gene in several human cancer cell lines.
Furthermore, siRNA knock down of the CSNK2A1P gene
decreased total CK2a protein level in cancer cells, indicating that
the CSNK2A1P gene is fully translated in cancer cells. Thus, the
amplification of the CSNK2A1P gene may play an oncogenic role
in these human cancer cell lines. On the basis of our results, we
propose that two functional genes may exist in the human CK2a
family, CSNK2A1, which locates on the chromosome 20p13, and
CSNK2A1P, which locates on the chromosome 11p15.3.
We also found a novel polymorphism within the kinase domain
(398T/C, which leads to amino acid change I133T, Figure 2a) in
101 primary tumors. This polymorphism appears to be evenly
distributed in normal tissue, but in tumors, is significantly more
frequent in the 398T allele (Table 2, Figure 2). The 398T allele
was selectively amplified in eighteen of the 101 lung cancer tissues,
suggesting it might provide a growth advantage over the 398C
allele. The 398C allele amplification was only found in two of the
101 lung cancer tissues, suggesting that it might be a random
event. These intriguing genetic results prompted us to probe more
deeply into the role of the variant CSNK2A1P forms in tumor
development. Doing so yielded two important findings, first, that
the 398T allele is more transforming than the 398C allele, and
second, that the 398T allele degrades tumor suppressor PML
protein more efficiently than the 398C allele. For instance, the
398T allele showed significantly higher transforming activity in
both colony formation and soft agar assays than the 398C allele
(Fig. 3B and C). The data of the kinase assay showed that the 398T
gene product has higher kinase activity than the 398C gene
product (Fig. 3D), suggesting that the 398T allele is a more
transforming allele than the 398C allele. In addition, these data
also suggest that the transforming ability of the 398T allele of the
CSNK2A1P pseudogene is similar to that of the normal CSNK2A1
gene product, so the more active allele of the pseudogene appears
to have activity comparable to the regular CSNK2A1 gene. To
date, there is no genetic or epigenetic evidence on the activation of
Figure 2. Allele-specific amplification of CSNK2A1P gene in lung cancer. (A) Allele-specific amplification of the 398T allele (TTT/C or TT/C) is
found in some non-small cell lung cancer tissue samples. The T above the arrowhead (nucleotide 398T, I133,) on the right is the indication of the wild-
type gene. (B) Amplification of CSNK2A1P alleles in lung tumors was validated by quantitative allele specific single polymorphism (SNP) analysis. The
ratio between the 398T and 398C alleles in heterozygous lung tumors was determined by TaqMan analysis using allele-specific probes and is
expressed as differences in CT levels (cycles) with positive or negative DCT values indicating amplification of the 398T or 398C allele, respectively. Of
56 samples typed, 2 showed amplification of the 398C allele greater than 0.6 CTs (samples T3–4) and 18 showed amplification of the 398T allele
(samples T5–23). Thirty-six samples showed no amplification (represented by T1–2). Normal controls samples showed no amplification (N1–3). The
normalized means and standard deviations of three independent experiments are shown. (C, D and E) Allele-specific amplification of the 398T allele
significantly increases in non-small cell lung cancer tissue samples. Normal: human adult normal genomic DNA. Tumor: no-small cell lung cancer
tissues. * denotes p,0.05 (Chi-square test).
doi:10.1371/journal.pone.0011418.g002
CK2 Pseudogene in Lung Cancer
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the first evidence that the CSNK2A1P 398T allele, which is similar
to the CSNK2A1 gene, is amplified in human lung cancer tissues.
The PML gene was originally identified at the breakpoint of
t(15;17) translocation in acute promyelocytic leukemia [17] and
was proved to be a tumor suppressor gene [18]. Loss of PML has
been correlated with poor clinical outcome in a variety of human
cancers, including lung cancer, supporting its tumor suppressor
function [5,19]. PML promotes the dephosphorylation of pRb and
regulates cell fate in the developing neocortex [20]. CK2 regulates
ubiquitin-mediated degradation of PML in human lung cancer cell
lines [5,21]. This may be one the potential mechanisms by which
the 398T allele is preferentially amplified in lung cancer samples.
This genetic polymorphism is probably a useful marker to detect
the amplification of the CK2 intronless gene, because monoallelic
amplification is believed to be responsible for gene amplification in
cancer [22]. This allele-specific amplification also implies that
cancer cells may be addicted to the oncogenic CK2a [23]. In
short, the amplification of the 398T allele of the CSNK2A1P gene
may contribute, at least in part, to the pathogenesis of lung cancer.
The CSNK2A1P gene is a processed pseudogene located on the
chromosome 11p15.3 and is supposed to be formed by retrotrans-
position, and characterized by the absence of introns, the presence of
flanking directs repeats,and the 39polyadenylationtail[15].However,
it has a strong promoter upstream from the initiation codon (14, 15).
The expression of the CSNK2A1P gene is potentially more tightly
regulated than the CSNK2A1 is. For instance, the promoter region of
the CSNK2A1P gene contains two TATA boxes and a CAAT box,
while the upstream sequence of CSNK2A1 displays housekeeping gene
characteristics, e.g., high GC content, the presence of several GC
boxes and the lack TATA box (14, 15). Moreover, several important
transcription factor-binding site s( e . g ,C E B P - ,G A T A - ,a n dS M A D -
binding sites) were predicted within the 59 region (1 Kb) from the
CSNK2A1P starting codon, suggesting that the CSNK2A1P gene may
potentially be induced or repressed by several master regulators of
developmental pathways. The amplification of the CSNK2A1P gene
could result in the overexpression of CSNK2A1P protein in cancer
cells. It may also be possible that the CSNK2A1 gene is somehow
indirectly regulated by the expression of the CSNK2A1P gene. Future
studies are needed to uncover the mechanism through which the
CSNK2A1P and the CSNK2A1 genes are regulated. Until now, around
10,000 processed pseudogenes [24] have been characterized in the
human genome, and some of these genes have been reported to be
expressed in cancer cells. For instance, the oncogenic CRIPTO3
pseudogene is expressed in colon, breast and lung cancers [25], the
human homologue of vaccinia virus H1 phosphotase gene clone 5
(hVH-5) pseudogene is expressed in breast cancer cell lines [26], and
the rac1 pseudogene is expressed in brain tumors [27]. Taken together
with our results, this suggests a potential oncogenic role of the
presumed pseudogenes in some human cancers.
This study had some limitations. We demonstrated the
correlation between CSNK2A1P gene and PML protein stability
in only two lung cancer cell lines in vitro. Specimens from only
101 lung cancer patients were analyzed, 56 of which were
heterozygous with respect to this polymorphism and could be used
for the analysis. In future studies, it will be important to include
additional cancer cell lines and more cancer tissues.
Our results provide genetic evidences for activation of the
intronless CK2a gene in human cancer. Although CK2 was
previously known to be a key player in cancer, its mechanism of
activation in cancer was not known [10,28]. Because of this lack of
knowledge about the mechanism of CK2 activation and its
constitutive activity, CK2 has been mostly neglected as a key
target for anti-cancer drugs. Since significant progress has been
made on the structural bases of CK2 inhibition, it is now possible
to develop potent and selective cell-permeable CK2 inhibitors
[29,30]. Understanding the difference in sequences of the
CSNK2A1P gene polymorphisms may allow us to design specific
diagnostic tests for human cancer. Importantly, our results support
the notion that protein kinase CK2a is an appealing target for
cancer therapeutics such as small-molecule inhibitors [10,31].
Materials and Methods
Cell lines
The human cancer (Jakurt, H1299, A549, A427, H441, H1703,
H322, H460, HCT116, H1975, H322, H358, H838, H28,
H2052, Hela and H1650) and normal lung (WI-38 and CCL-
211) cell lines were obtained from American Type Culture
Collections (Manassas, VA). H290 and MS-1 cell lines were
obtained from NIH (Frederick, MD). Cells were grown in
complete growth medium (Dulbecco’s modified Eagle’s medium
Table 2. DNA sequencing results of the 398 allele in 101 lung
cancer tissues samples and genomic DNA from 48 normal
adults.




CC/T 2 (2%) 0 (0%)
TT/C or TTT/C 18 (17.8%) 0 (0%)
T 35 (34.6%) 12 (25%)
C/T or T/C 36 (35.6%) 24 (50%)
C 10 (10%) 12 (25%)
doi:10.1371/journal.pone.0011418.t002
Table 1. DNA sequencing results of the 398 allele in cancer
cell lines.
Cell line type and name 398T 398T/C 398C
Lung cancer H1299 +
Lung cancer A549 +
Lung cancer A427 +
Lung cancer H322 +
Lung cancer H358 +
Lung cancer H441 +
Lung cancer H460 +
Lung cancer H838 +
Lung cancer H1650 +
Lung cancer H1703 +
Lung cancer H1975 +
T cell leukemia Jurkat +
Colon cancer HCT116 +
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Medium for WI-38 ; Roswell Park Memorial Institute’s medium
for H1299, A549, A427, H441, H1703, H322, H460, HCT116,
H1975, H322, H358, H838, H28, H2052 and H1650) supple-
mented with 10% fetal bovine serum, 10 units/ml penicillin and
10 mg/ml streptomycin at 37uC and 5% CO2.
Tissue samples
Fresh tumor tissues and adjacent normal tissues were obtained
from patients with non-small cell lung cancer (NSLC) who were
undergoing surgical resection of the primary tumor. The study was
approved by the University of California, San Francisco,
institutional review board (CHR# H8714-11647-14). We ob-
tained written informed consents from all participants involved in
our study. Tissue samples were kept at 2180uC liquid nitrogen
freezers before use, and final pathologic diagnosis was confirmed
by a pathologist at the University of California, San Francisco
(UCSF), USA. Normal adult genomic DNA form peripheral blood
was purchased from BioChain (Hayward, CA).
Fluorescence-in situ hybridization
The fluorescence-in situ hybridization (FISH) probe for
CSNK2A1P (RP11-567I13, chromosome 11p15.3) was purchased
from BACPAC Resources (Oakland, CA). The chromosome 11
centromere was labeled by Vysis CEP 11 SpectrumGreen
TM
probe (Abbott Molecular, Abbott Park, IL). Metaphase slides were
prepared using standard protocols of the UCSF Molecular
Pathology Core facility. All hybridizations were done by the
UCSF Molecular Pathology Core facility. The CSNK2A1P BAC
probe was labeled with Cy3 red by nick translation. Probe mixture
was prepared according to the standard protocol.
DNA and cDNA sequencing analysis
Genomic DNA or total RNA was isolated from cell lines and
tissue samples using the DNeasy Blood & Tissue Kit or the
RNeasy Mini Kit (Qiagen Valencia,CA), respectively. The
CSNK2A1P gene was PCR amplified using its gene-specific
primers. The forward and reverse primers used for PCR and
sequencing were: 59-AGAAAATTGCTCCCCACTCC-39 and 59-
GTGCTGCCAGAGAATGA CAA-39 respectively. The PCR
products were gel-purified using the QIAquick Gel Extraction kit
(Qiagen Valencia,CA) and were subsequently sequenced at
MCLab (South San Francisco, CA).
Semi-quantitative reverse transcription-PCR (RT-PCR)
analysis
Total RNA from cell lines and tissues was isolated using an
extraction kit, and DNA was eliminated by on-column treatment
Figure 3. Differential transforming activity of the two CSNK2A1P alleles. (A) The CSNK2A1 and CSNK2A1P genes were transiently transfected
into 293T and NIH3T3 cells using Lipofectamine 2000 Reagent according to manufacture’s protocol. 72 hours after transfection, cells were harvest
and total cellular proteins were extracted. Western blot analysis was used to confirm the protein expression in both alleles of the CSNK2A1P gene.
Anti-Myc tag antibody was used to detect the CSNK2A1P-Myc tag fusion proteins. (B) Colony formation assay. Transfection of CSNK2A1P gene in
NIH3T3 cells results in enhanced anchorage-dependent growth, compared to the empty vector control. The colony numbers of NIH3T3-CSNK2A1 and
NIH3T3-CSNK2A1P cells are dramatically higher than those of the NIH3T3-EV cells. (C) Soft agar assay. Stable transfection of CSNK2A1P genes in
NIH3T3 cells results in enhanced anchorage-independent growth. Both the NIH3T3-CSNK2A1 and NIH3T3-CSNK2A1P cells produced significantly
more colonies than the NIH3T3-EV cells did (*p,0.05, t-test). Of the two alleles of the CSNK2A1P gene, the 398T allele formed more colonies than the
398C allele did (**p,0.05, t-test). Relative colony formation in both cell lines is expressed as percentage normalized to empty-vector-transfected
control group and shown as bar 6 standard deviation in three independent experiments. (D) Kinase assay of the expressed CSNK2A1 and CSNK2A1P
proteins in NIH3T3 cells. The expressed proteins were immune-precipitated with Anti-Myc tag antibody and kinase assay was performed. Both the
NIH3T3-CSNK2A1 and NIH3T3-CSNK2A1P cells had significantly higher kinase activities than the NIH3T3-EV cells did (*p,0.05, t-test). Of the two
alleles of the CSNK2A1P gene, the 398T allele cells had significantly higher kinase activity than the 398C allele did (**p,0.05, t-test). Relative kinase
activity is expressed as percentage normalized to empty-vector-transfected control group and shown as bar 6 standard deviation in three
independent experiments. EV: empty vector. Wt: CSNK2A1. 398C: CSNK2A1P (I133) 398T: CSNK2A1P (I133T).
doi:10.1371/journal.pone.0011418.g003
CK2 Pseudogene in Lung Cancer
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Semiquantitative RT-PCR was performed by using SuperScript
One-step RT-PCR with Platinum Taq kit (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. One-step RT-PCR
was performed using pairs of CSNK2A1P-specific primers
(Forward: 59-AGAAAATTGCTCC CCACTCC-39 and Reverse:
59-GTGCTGCCAGAGA ATGACAA-39), CSNK2A1-specific
primers (Forward: 59-TGGGGACAGAAGATTTATATGA-39
and Reverse: 59-CTGAAGAAATCCCTGACA TCAT-39)a n d
CSNK2B-specific primers (Forward: 59-CAGGTCCCTCAC-
TACCGACA -39 and Reverse: 59-CAGCTGGTAGGCCATCG-
GAT-39). The PCR products were verified by direct DNA
sequencing. Glyceraldehyde-3-phosphatedehydrogenase (GAPDH)
was used as an internal control. Amplification conditions for
CSNK2A1P, CSNK2A1 and CSNK2B were as follows: 1 cycle of
45uC for 30 min, followed by 1 cycle of 95uC for 5 min, and 35
cycles of 95uC for 1 min, 56uC for 1 min, 72uC for 1 min and 1
cycle of 72uC for 10 min then 4uC.
Figure 4. Functional polymorphism of the CSNK2A1P genes on the degradation of PML tumor suppressor protein. (A) The PML protein
decreases in NIH3T3 and H1650 stable cell lines that were transfected by the CSNK2A1 and CSNK2A1P genes. The endogenous CSNK2A1 protein and
overexpressed CSNK2A1 and CSNK2A1P proteins were also shown. (B) Degradation of the PML protein is more prominent in NIH3T3 stable cell lines
transfected with CSNK2A1 and CSNK2A1P (I133). Hr: hours after cycloheximide treatment. (C) 293T cells were co-transfected with PML-V5 and Myc-
tagged CSNK2A1 or CSNK2A1P constructs. CSNK2A1 and CSNK2A1P (I133) show stronger binding to the PML protein in reciprocal
immunoprecipitation assays. EV: empty vector. Wt: CSNK2A1. 398T: CSNK2A1P (I133) 398C: CSNK2A1P (I133T). (D) The expression of the CSNK2A1P
gene decreases in the H1299 lung cancer cell line after transfection with the CSNK2A1P gene specific siRNA. No decrease in the expression of the
CSNK2A1 and CSNK2B genes were noted. (E) The CK2a protein level decreases and the PML protein level increases in the H1299 lung cancer cell line
after transfection with the CSNK2A1P gene specific siRNA. N: negative control siRNA. CSNK2A1P: CSNK2A1P siRNA. The band densities are normalized
to the negative siRNA transfected group using actin as an internal control. All experiments were repeated three times with similar results.
doi:10.1371/journal.pone.0011418.g004
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The full-length cDNA of CSNK2A1P gene from A549 cells was
cloned using TOPO TA Cloning Kit (Invitrogen Carlsbad, CA),
and then was subcloned into the HindIII and BamHI sites of the
pcDNA3.1/myc-His vector (Invitrogen, Carlsbad, CA). The
forward and reverse primers used for cloning were 59-
CCTTAAAAGCTTGACCATGTCGG GACCCGTGCCAAG-
39and59-CCTTAAGGATCCGACTGCTGAGCGCCAGCGG-
CAG-399respectively. The CSNK2 A1pcDNA3.1/myc-His vector
was a gift from Dr. L. A. Pinna. Both myc-His tagged CSNK2A1
andCSNK2A1PgenesweresubsequentlyclonedintotheSnaBIsite
of the pBabe-puro vector. The forward and reverse primers used for
cloning were 59-GGCTAGTTTACGTAG ACCATG TCGG-
GACCCGTG CCAAG-39 and 59-AAGGCACAGT CGACGCT
GATCAGCGGGTT TAAACTCA-39 respectively. All resultant
vectors were verified by direct DNA sequencing.
Retroviral production and transduction
The CSNK2A1 and CSNK2A1P retroviral vectors were then
transfected into the HEK 293 Phoenix ampho packaging cells
(ATCC, Manassas, VA) by using Fu-GENE6 transfection reagent
(Roche, Lewes, UK) to produce retroviral supernatants. Forty-
eight hours after transfection, the supernatant was filtered through
a 0.45 mm syringe filter. Retroviral infection was performed by
adding filtered supernatant to mesothelioma cell lines cultured on
10cm dishes with 50% confluent in the presence 8 ug/ml of
polybrene (Sigma, St. Louis, MO). Six hours after infection, the
culture medium was replaced with fresh medium and infected cells
were allowed to recover for 48 hours. Infected cells were selected
by adding 1mg/ml puromycin (Sigma, St. Louis, MO) to the
culture medium for 48 hours and then maintained in complete
medium with 0.5mg/ml puromycin. Empty retroviral infected
stable cell lines were also produced by the above protocols.
Western blot analysis
Whole protein was extracted by M-PER Mammalian Protein
Extraction Reagent from cell lines added with Phosphatase
Inhibitor Cocktail Set II (Calbiochem, San Diego, CA) and
Complete Protease Inhibitor Cocktails (Roche, Lewes, UK)
according to manufactures’ protocols. The proteins were separated
on 4–15% gradient SDS–polyacrylamide gels and transferred to
Immobilon-P membranes (Millipore, Bellerica, MA). The follow-
ing primary antibodies were used: anti-CK2a, anti-b-actin (Sigma
Chemical, St. Louis, MO), anti-PML (Santa Cruz, Santa Cruz,
CA), and anti-Myc tag (Cell Signaling, Danvers, MA). After being
incubated with appropriate secondary antibodies, the antigen-
antibody complexes were detected by using an ECL blotting
analysis system (Amersham Pharmacia Biotech, Piscataway, NJ).
Colony formation assay
NIH3T3 cells stably transfected with CSNK2A1 or
CSNK2A1P (5610
2) were plated in 10 cm culture dishes and
incubated in complete medium for 14 days. The colonies were
then stained with 0.1% crystal violet, and colonies greater then 50
cells were counted. Results were expressed as relative colony
formation: percentage of the number of colonies relative to the
empty vector transfected controls. Three independent experiments
were performed.
Soft agar growth assay
For experiments using the pcDNA3.1/myc-His vectors express-
ing CSNK2A1 and CSNK2A1P, NIH3T3 cells were transfected
with these vectors or control empty vector and then selected in
100 ug/ml of G418 for 1 week. Cells (1610
3) were then cultured
in DMEM plus 15% FBS in 0.35% (w/v) low melting temperature
agar between layers of 0.7% low melting temperature agar. After 4
weeks, colonies were stained with 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma Chemical Co.), and colonies
containing .100 cells were scored. Colonies were photographed
and counted after staining.
Protein degradation assay
The stable NIH3T3 cells retrovirally transfected with
CSNK2A1 and CSNK2A1P were plated on 6 cm culture dishes.
At 80% confluence, cells were exposed to 20 mg/ml cycloheximide
and harvested at different time points (0, 2 and 6 hours). Total
cellular proteins were extracted and were analyzed by western blot
analysis using b-actin as the loading control.
Co-immunoprecipitation assay
293T cells were transiently co-transfected with PML pcDNA4/
V5-His (a gift from Dr. Zheng Pan) and CSNK2A1 or
CSNK2A1P pcDNA3.1/myc-His vectors with Lipofectamine
2000 transfection reagent (Invitrogen Carlsbad, CA). Twenty-four
hours after transfection, cells were treated with 10mM of MG132
(Sigma, St. Louis, MO) and then harvested in NP-40 lysis buffer
(150 mM NaCl, 50 mM Tris [pH 8.0], 1% NP40), protease
inhibitor, and phosphatase inhibitor cocktail (Roche, Lewes, UK).
Immunoprecipitation was performed by the Catch and Release
v2.0 Reversible Immunoprecipitation System (Millipore, Bellerica,
MA) according to the manufacturer’s protocols. Anti-Myc tag
(Santa Cruz, Santa Cruz, CA) and anti-V5 tag (Invitrogen,
Carlsbad, CA) antibodies were used for immunoprecipitation
respectively.
Transfection of small interfering RNA
Pre-designed and validated CSNK2A1P and universal negative
control small interfering RNAs (siRNA) were purchased from
Invitrogen (Carlsbad, CA). Transfection was performed using
Lipofectamine
TM RNAiMAX Transfection Reagent (Invitrogen),
according to the manufacturer’s manual. Cells were plated in 60-
mm dishes in antibiotic-free media and transfection was performed
with cells at 60% confluence with a final concentration of 50 nM
for each siRNA. At 72 hours after transfection, cells were analyzed
for gene and protein expression.
Allele-specific amplification assays
The allele-specific amplification was measured using the ABI
PRISM 7700 sequence detection system. PCR reactions for allele-
specific expression (5 ml) contained 10 ng genomic DNA, 16
TaqMan universal PCR master mix, forward and reverse primers
(900 nM), 200 nM VIC-labeled probe and 200 nM FAM-labeled
probe. Amplification conditions were as follows: 1 cycle of 95uC
for 10 min, followed by 40 cycles of 95uC for 15 s and 63uC for
1 min. The data was analyzed using the Allelic Discrimination
Sequence Detection Software (Applied Biosystems). The TaqMan
primers and probes were custom designed using the Primer
Express Oligo Design Software (Applied Biosystems). Probes were
MGB probes were designed specifically for TaqMan Allelic
Discrimination (Applied Biosystems). Primer sequences are 59-
CCGCCTTGGTTTTTGAACAC-39and 59-GGCCTTCAGAA-
TCTCATACATGTAAA-39; probe sequences are FAM-CACA-
GACTATGACTC (398C allele specific) and VIC-TCACAGAC-
TATGATTC (398T allele specific). PCR was done in triplicate for
each sample and experiments were repeated at least three times.
CT values were normalized to the average normal genomic CT
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the two probes for the triplicates were then averaged.
Kinase assays
For determination of the kinase activity of the expressed
CSNK2A1 and CSNK2A1P proteins, Casein Kinase 2 Assay Kit
(Millipore, Bedford, MA) was used according to manufacture’s
protocol. Stable NIH3T3 cells transfected with the CSNK2A1 and
CSNK2A1P genes were harvested in NP-40 lysis buffer (150 mM
NaCl, 50 mM Tris [pH 8.0], 1% NP40), protease inhibitor, and
phosphatase inhibitor cocktail (Roche, Lewes, UK). Immunopre-
cipitation was performed by the Catch and Release v2.0
Reversible Immunoprecipitation System (Millipore, Bellerica,
MA) according to the manufacturer’s protocols. Anti-Myc tag
(Santa Cruz, Santa Cruz, CA) antibody was used for immuno-
precipitation. Kinase assay was carried in a final volume of 50 ml
containing 20 mM MOPS (pH 7.2), 25 mM b-glycerol phosphate,
5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol,
15 mM Mgcl2, 200 mM for CK2 substrate peptide:
RRRDDDSDDD (Millipore, Bedford, MA), and [c-33P]-ATP.
After incubation in 30uC for 20 minutes, assay was stopped by
adding of 20 ml 4% trichloroacetic acid and transferred 25 mlt o
P81 phosphocellulose squares. After washing with 0.75% phos-
phoric acid for 6 times and with acetone for 1 time,
phosphocellulose squares were dried and transferred to scintilla-
tion vials for counting.
Statistical analysis
The data are shown as mean values 6 standard deviation (SD).
Student’s t-test was used to compare results between control and
experimental groups in the colony formation assay. Chi-square test
was used to compare the frequency of the CSNK2A1P polymor-
phisms between lung cancer tissues and normal controls. Pearson
correlation coefficient was used to access the correlation between
mRNA expression and copy numbers of the CSNK2A1P gene in
cancer cell lines. Statistical analysis was carried out using SPSS
(version 10.0, Chicago, IL). A P value of less than 0.05 was
considered statistically significant. All statistical tests were two-
sided.
Supporting Information
Figure S1 Alignment of primers for semi-quantitative RT-PCR
of the CSNK2A1P (F1 and R1) and CSNK2A1 (F2 and R2) genes.
Primers used for PCR and DNA sequencing (F1 and R3) were also
shown. Open reading frames of both genes were represented by
the solid bars. Regions specific to the CSNK2A1P gene was
represented as the thin hollow bar. The vertical arrows indicate
the differences of the sequences between the CSNK2A1 and
CSNK2A1P genes used for designing of primers. F1: 59-
AGAAAATTGCTCC CCACTCC-39. R1: 59-GTGCTGCCA-
GAGA ATGACAA-39), F2: 59-TGGGGACAGAAGATTTA-
TATGA-39. R2: 59-CTGAAGAAATCCCTGACA TCAT-39).
R3: 59-GTGCTGCCAGAGAATGA CAA-3.
Found at: doi:10.1371/journal.pone.0011418.s001 (0.05 MB
DOC)
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